Wednesday November 22, 2017 16:34

Heathcare Press Release : 06 Nov 2017

Switching to Tresiba(R) is Highly Cost-effective and Cost-saving in a Real-world Heathcare—06 Nov 17

A new analysis of real-world data has shown that switching to Tresiba(R) (insulin degludec) is highly cost-effective and cost-saving for the treatment of type 1 and type 2 diabetes, respectively.[1] The analysis was presented today at the International